Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug candidate targets Hard-to-Treat cancers in early trial

NCT ID NCT05156866

First seen Jan 19, 2026 · Last updated Apr 30, 2026 · Updated 15 times

Summary

This early-stage study tests a new drug, TORL-2-307-ADC, in people with advanced solid tumors, including gastric, pancreatic, and gastroesophageal junction cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 163 participants will receive the drug to help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana, 46804, United States

  • Providence St. Jude Medical Center

    Fullerton, California, 92835, United States

  • START San Antonio

    San Antonio, Texas, 78229, United States

  • Seoul National University Bundang Hospital

    Seoul, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Texas Oncology-Austin

    Austin, Texas, 78705, United States

  • Texas Oncology-Dallas

    Dallas, Texas, 75246, United States

  • Texas Oncology-Tyler

    Tyler, Texas, 75702, United States

  • Torrance Memorial Medical

    Torrance, California, 90505, United States

  • UCLA - JCCC Clinical Research Unit

    Los Angeles, California, 90095, United States

  • Washington University School of Medicine-Siteman Cancer Center

    St Louis, Missouri, 63310, United States

Conditions

Explore the condition pages connected to this study.